Shares of Biocept, Inc. (NASDAQ:BIOC) have received an average recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $2.50.

Several equities research analysts recently weighed in on BIOC shares. Zacks Investment Research cut Biocept from a “buy” rating to a “hold” rating in a research note on Thursday, June 1st. ValuEngine cut Biocept from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 8th. Finally, Westpark Capital restated an “outperform” rating on shares of Biocept in a research note on Thursday, August 3rd.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

Biocept (NASDAQ:BIOC) opened at 1.30 on Friday. Biocept has a 12-month low of $0.74 and a 12-month high of $3.39. The stock’s 50 day moving average is $1.28 and its 200 day moving average is $1.59. The firm’s market cap is $39.33 million.

Biocept (NASDAQ:BIOC) last posted its earnings results on Thursday, August 10th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.23 million. Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. On average, equities research analysts expect that Biocept will post ($0.79) EPS for the current year.

A hedge fund recently raised its stake in Biocept stock. Creative Planning increased its holdings in shares of Biocept, Inc. (NASDAQ:BIOC) by 64,679.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 246,811 shares of the medical research company’s stock after purchasing an additional 246,430 shares during the quarter. Creative Planning owned approximately 0.93% of Biocept worth $338,000 at the end of the most recent quarter. 6.92% of the stock is owned by institutional investors.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with's FREE daily email newsletter.